Artesunate overcomes the resistance of basal type of bladder cancer to RC48
ERBB2 expression mediates sensitivity of bladder cancer cells to RC48. JAK/STAT3 pathways compensatory activation after exposing RC48. A combination of STAT3 inhibitor-artesunate and RC48 could significantly inhibit basal bladder cancer growth. These findings provided a theoretical foundation for subsequent individualized therapy for MIBC based on the molecular types. Overall design: Comparative gene expression profiling analysis of RNA-seq data for SW780 and RC48-exposed SW780 cells.